• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Prime Medicine Inc (NQ: PRME )

    4.030 +0.150 (+3.87%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Prime Medicine Inc

    < Previous 1 2 Next >
    Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Unveils Strategically Focused Pipeline
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine to Participate in Upcoming Investor Conferences
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine to Present at Upcoming Investor Conferences
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine to Participate in Upcoming Investor Conferences
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Announces Pricing of Upsized Public Offering
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Announces Proposed Public Offering of Common Stock
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
    From Prime Medicine, Inc.
    Via GlobeNewswire
    2 gene editing stocks to keep on your 2024 watchlist
    Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) 
    Via MarketBeat
    Exposures Product Safety
    Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine to Present at Upcoming Investor Conferences
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine to Present at Upcoming Investor Conferences
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine to Present at Upcoming Investor Conferences
    From Prime Medicine, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.